I'll expect a full report from Erik on each pres'n. :-)
++++++++++++++++++
Significant Data on VELCADE(R) (bortezomib) For Injection To Be Presented at Upcoming American Society of Hematology Meeting
prnews
-- Data from studies across a broad spectrum of hematological cancers featured in 153 abstracts, including 27 oral presentations and VELCADE combination therapy poster session --
CAMBRIDGE, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that new data from
studies of VELCADE will be featured at the American Society of Hematology
(ASH) 48th Annual Meeting in Orlando, Fla., December 9-12, 2006.
(Logo: newscom.com )
"Data continue to show how VELCADE, the only approved product that
provides a survival advantage to patients with relapsed multiple myeloma, is
showing encouraging results in combination with standard therapies in multiple
myeloma and non-Hodgkin's lymphoma," said Deborah Dunsire, M.D., President and
CEO, Millennium. "Over 150 abstracts will be presented this week showing some
of the highest complete response rates seen to date in the treatment of
multiple myeloma in the non-transplant setting."
Highlights from oral and poster presentations of VELCADE include:
Multiple Myeloma: Front Line
(Abstract #56, Sunday 10th December, 4:45 p.m.), Lead Investigator: Jean-
Luc Harousseau, M.D., Hospital Hotel-Dieu, Nantes, France
* Preliminary data from a Phase III study of newly diagnosed multiple
myeloma (MM) patients treated with VELCADE plus dexamethasone versus
vincristine, adriamycin and dexamethasone combination therapy (VAD)
(Abstract #796, Tuesday 12th December, 8:45 a.m.), Lead Investigator:
Sundar Jagannath, M.D., St. Vincent's Comprehensive Cancer Center, New York,
on behalf of the Aptium Oncology Research Network, Los Angeles, California
* Long-term follow-up on a Phase II trial of MM patients treated with
VELCADE alone and in combination with dexamethasone as front-line
therapy
(Abstract #797, Tuesday 12th December, 9:00 a.m.), Lead Investigator:
Robert Orlowski, M.D., Ph.D., Lineberger Comprehensive Cancer Center,
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
* VELCADE plus pegylated liposomal doxorubicin as induction therapy for
patients with untreated MM
(Abstract #3093, Monday 11th December, 10:30 a.m.), Lead Investigator:
Andrzej Jakubowiak, M.D., Ph.D., University of Michigan Comprehensive Cancer
Center, Ann Arbor, Michigan
* Preliminary data from a study of VELCADE plus Doxil and dexamethasone in
untreated MM patients, and the efficacy of this regimen following
autologous stem cell transplant
Multiple Myeloma: Relapsed/Refractory
(Abstract #404, Monday 11th December, 11:15 a.m.), Lead Investigator:
Robert Orlowski, M.D., Ph.D., Lineberger Comprehensive Cancer Center,
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
* Interim analysis of a Phase III study of VELCADE in combination with
pegylated liposomal doxorubicin compared with VELCADE alone in
relapsed/refractory MM patients
(Abstract #3530, Monday 11th December, 10:30 a.m.), Lead Investigator:
Joseph Mikhael, M.D., Princess Margaret Hospital, Toronto, Canada
* Preliminary Phase IIIb data from a study of biweekly VELCADE ±
dexamethasone in patients with relapsed/ refractory MM, including those
who were heavily pretreated
(Abstract #3529, Monday 11th December, 10:30 a.m.), Lead Investigator:
Ruben Niesvizky, M.D., Weill Medical College of Cornell University, New York
Presbyterian Hospital, New York
* Analysis of the Phase III APEX and Phase II SUMMIT trials evaluating the
relationship between quality of response to VELCADE and clinical benefit
in relapsed/refractory MM
(Abstract #405, Monday 11th December, 11:30 a.m.), Lead Investigator: Paul
Richardson, M.D., Dana-Farber Cancer Institute, Boston, Massachusetts
* Final data from a multicenter Phase I trial of VELCADE in combination
with lenalidomide and dexamethasone in heavily pretreated relapsed MM
patients, including those who had prior treatment with VELCADE,
lenalidomide, thalidomide and stem cell transplant
(Abstract #3537, Monday 11th December, 10:30 a.m.), Lead Investigator:
Faith Davies, M.D., Haemato-Oncology Unit, Royal Marsden Hospital, London,
England
* Interim data from a retrospective study of VELCADE plus dexamethasone
and cyclophosphamide compared to VELCADE alone and VELCADE plus
dexamethasone for patients with multiply relapsed MM
(Abstract #3539, Monday 11th December, 10:30 a.m.), Lead Investigator:
Asher Chanan-khan, M.D., Roswell Park Cancer Institute, State University of
New York at Buffalo, New York
* Final results of a Phase II Study of VELCADE in combination with
pegylated liposomal doxorubicin and thalidomide (VDT) in relapsed MM
patients, targeting the MM cell and its microenvironment
(Abstract #3536, Monday 11th December, 10:30 a.m.), Lead Investigator:
Donna Reece, M.D., Princess Margaret Hospital, University Health Network,
Toronto, Ontario
* Results from a Phase I/II dose-escalating study of VELCADE plus oral
cyclophosphamide and prednisone for relapsed MM
(Abstract #3541, Monday 11th Dec., 10:30 a.m.), Lead Investigator:
Evangelos Terpos, M.D., Dept. of Hematology, General Airforce Hospital,
Athens, Greece
* VELCADE in combination with melphalan, dexamethasone and intermittent
thalidomide (VMDT) in relapsed/refractory MM, and impact of the regimen
on markers of bone remodeling
(Abstract #407, Monday 11th December, 12:00 p.m.), Lead Investigator:
Antonio Palumbo, M.D., Azienda Ospedaliera San Giovanni Battista, Torino,
Italy
* Results of a Phase I/II clinical trial of VELCADE in combination with
melphalan, prednisone and thalidomide (VMPT) for relapsed MM
Multiple Myeloma: Retreatment
(Abstract #3531, Monday 11th December, 10:30 a.m.), Lead Investigator:
Therese Conner, Outcomes Research, U.S. Oncology, Houston, Texas
* Efficacy of single-agent VELCADE as retreatment in relapsed MM patients
(Abstract #3532, Monday 11th December, 10:30 a.m.), Lead Investigator:
Jeffrey Wolf, M.D., Alta Bates Comprehensive Cancer Center, Berkeley,
California
* VELCADE as retreatment in heavily pretreated relapsed MM patients: A
retrospective analysis of the Phase II SUMMIT and CREST and Phase III
APEX studies
Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma (Abstract #2753, Sunday 10th December, 9:00 a.m.),
Lead Investigator: Johannes Drach, M.D., Department of Medicine I, Clinical
Division of Oncology, Medical University of Vienna, Austria
* Phase II interim results of the study of VELCADE plus rituximab and
dexamethasone in relapsed/refractory mantle cell lymphoma
Follicular and Marginal Zone Lymphoma (Abstract #694, Monday 11th
December, 4:15 p.m.), Lead Investigator: Sven De Vos, M.D., Ph.D., UCLA
Medical Center, Los Angeles, California
* Final results of a Phase II study with weekly and twice-weekly VELCADE
plus rituximab in relapsed/refractory follicular and marginal zone
lymphomas
B-cell Non-Hodgkin's Lymphoma (Abstract #2759, Sunday 10th December, 9:00
a.m.), Lead Investigator: John Gerecitano, M.D., Memorial Sloan-Kettering
Cancer Center, New York, New York
* Final results of a Phase I study of VELCADE plus rituximab,
cyclophosphamide and prednisone (R-CVP) in relapsed/refractory B-cell
non-Hodgkin's Lymphoma
T-Cell Lymphoma (Abstract #2462, Sunday 10th December, 9:00 a.m.), Lead
Investigator: Pier Luigi Zinzani, M.D., Unit of Cardiology and Hematology,
Institute of Hematology and Medical Oncology, University of Bologna, Bologna,
Italy
* Preliminary results of a Phase II study of single-agent VELCADE in
previously treated patients with relapsed peripheral T-cell lymphoma,
unspecified with only skin involvement and cutaneous T-cell lymphomas |
